Dr. Alan Robin is a leader in the clinical management and scientific study of glaucoma as well as the global impact of eye care. Dr. Robin holds joint Associate Professorships in Ophthalmology and in International Health at Johns Hopkins University and has been a Clinical Professor at the University of Maryland. He has been the co-director of the Glaucoma Service at the Greater Baltimore Medical Center and holds an active private practice with offices in the Baltimore and southern Pennsylvania areas. Additionally he is a Professor of Ophthalmology at the VA system and is actively involved with teaching optometry as well as ophthalmology. In fact he has trained as fellows and residents dozens of current departmental chairs.

Dr. Robin attended Yale University and Tufts University School of Medicine. He completed his fellowship at the Wilmer Institute. He was a HEED fellow and a recipient of two NIH RO1 grants , and has been an active clinical investigator in initial studies of widely used glaucoma medications including apraclonidine, latanoprost, brimonidine, and brinzolamide. He was the principal investigator for Coherent Medical in support of Nd:YAG laser iridotomy. He was the principal investigator in the Aravind Comprehensive Eye Study, a prevalence study in Tamil Nadu, India. Dr. Robin has published seminal articles on the use of lasers, drugs, and surgery for glaucoma treatments in addition to manuscripts on cost effectiveness and adherence. He holds patents for interactive diagnostic algorithms for glaucoma, medication delivery systems, and glaucoma surgical devices.

His current research interests have included the use of newer delivery systems for medications to treat open angle glaucoma and in improving adherence to glaucoma therapies. He is also deeply involved in both the global eradication of needless blindness and establishing strategies for better eye care delivery. Dr. Robin has authored or co-authored over 190 peer-reviewed papers, 24 book chapters, and given well over 100 invited lectures both in the US and in Canada, Australia, New Zealand, Europe, Japan, South America, India, and South East Asia. He serves as editor or reviewer for numerous journals including *Ophthalmology, Archives of Ophthalmology, American Journal of Ophthalmology, Journal of Glaucoma, Graefes Archives, British Journal of Ophthalmology, Ophthalmic Epidemiology, and Eye.*

Dr. Robin has worked as a consultant to the FDA and as a consultant to industry to develop protocols and problem solve with the FDA. He has helped get medications approved with the VA system and has worked closely both with the American Academy of Ophthalmology and with managed care in formulary matters. He is a currently a member of the ANSI committee to develop new FDA algorithms for approving early stage glaucoma surgical devices.

He has won many honors and awards during his career, among them the senior honor and Secretariat awards of the AAO, the Outstanding Humanitarian Service award of the AAO, Dr Venkataswamy Oration Award, and the silver achievement award of the Associate of Ophthalmology and Visual Sciences. He will be receiving the 2014 Humanitarian award from the American glaucoma society in February 2014. As he is noted for his intellect and scientific ability, he is also noted for his selfless humanitarian work both in the US and globally.

He is also a member of or consultant to the International Association to Prevent Blindness, SEVA Foundation, Tissue Banks International, ORBIS International, Aravind Eye Foundation, and the World Health Organization. Dr. Robin has made over 70 trips to India and Nepal since the 1980s and worked closely with Dr. Ruit in Kathmandu and the Aravind Eye Institute. He is instrumental in establishing its glaucoma service and still serves as its co-director. He is an honorary member of both the Indian and Nepal Ophthalmological Societies.